



*Small, but heading for the big time*

## ***Nanobiotix revenue for the 1<sup>st</sup> quarter of 2014 and new composition of the shareholding***

**Paris, France, May 12, 2014 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205)**, a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the first quarter of 2014 and presents the new breakdown of its share capital pursuant to the capital increase with preferential subscription rights completed in March 2014.

### **Income statement**

<i>In €</i>	<i>Q1 2014</i>	<i>Q1 2013</i>
<b>Revenues</b>	<b>45,343</b>	<b>46,481</b>
Of which :		
<i>License</i>	45,343	46,481
<i>Services</i>	-	-


### **Activity**

The revenue recorded by NANOBIOTIX during the first quarter of 2014 corresponds to the upfront payment (pro-rata share) received by the company from Taiwan-based PharmaEngine, within the framework of the licensing contract. This licensing contract was signed with PharmaEngine in August 2012 for the development and commercialization of the lead product, NBTXR3 in the Asia-Pacific region. The total upfront payment totaled €810,640 and is apportioned using the straight-line method across the period between the date the contract was signed and the scheduled marketing launch in the region which is anticipated as 2017.

During the quarter, the most significant event has been a capital increase with preferential subscription rights. The subscription ratio was 3 new shares for 14 existing shares at a subscription price of €10.60 per share. The capital increase was successfully completed on 20 March 2014 and the total amount raised was €28.1 million, after full exercise of the extension clause. The settlement-delivery and the trading of the new shares occurred on 24 March 2014. The rationale for raising these funds was mainly to support the acceleration of the product pipeline.

The company believes that the coming year is going to be a pivotal one for its development, in particular with respect to operational and clinical progress.

**New composition of Nanobiotix shareholding structure following the capital increase which took place in March 2014**



Following the completion of the capital increase, the original institutional shareholders remaining invested in the company represent 30.2% of its capital. A great number of new shareholders have acquired shares, with a significant increase of retail shareholders (43.6% of the capital against 13.1% previously), and with the arrival of a large number of foreign (non-French) institutional investors (79 shareholders representing 10.7% of the capital compared to 2% previously) mainly from Belgium, the Netherlands, Luxembourg and Italy.

Although the capital increase has resulted in an increase in the number of French institutional investors (from 4 to 30), their aggregate proportion decreased from 15% to 8.2%.

In total, institutional investors represent 49.1% of the capital.

**Next financial press release: revenue for the second quarter of 2014, on July 11, 2014**



**About NANBIOTIX:** [www.nanobiotix.com/fr](http://www.nanobiotix.com/fr)

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO:FP).

## Contacts

---

### **Nanobiotix**

**Sarah Gaubert**

*Head of Communication and Public Affairs*

+33 (0)1 40 26 07 55

[contact@nanobiotix.com](mailto:contact@nanobiotix.com)

---

### *Financial communication and investors relations*

**NewCap**

**Louis-Victor Delouvier / Emmanuel Huynh**

+33 (0)1 44 71 98 53

[lvdelouvier@newcap.fr](mailto:lvdelouvier@newcap.fr)



---

### *Media relations*

France - **NewCap**

**Annie-Florence Loyer / Nadège Le Lezec**

+33 (0)6 88 20 35 59

[afloyer@newcap.fr](mailto:afloyer@newcap.fr) / [nlelezed@newcap.fr](mailto:nlelezed@newcap.fr)

Outside France - **Instinctif Partners** (formerly College Hill)

**Melanie Toyne Sewell / Katherine Lynch / Donia Al Saffar**

+44 (0) 207 457 2020

[nanobiotix@instinctif.com](mailto:nanobiotix@instinctif.com)